Increased Ciprofloxacin Resistance in Gonococci Isolated in Scotland

Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Increased Ciprofloxacin Resistance in Gonococci Isolated in Scotland

Lancet (www.thelancet.com) (12/09/00) Vol. 356, No. 9246, P. 1984
Forsyth, Aileen; Moyes, Alex; Young, Hugh

There is evidence in Scotland of a strain of Neisseria gonorrhoeae resistant to the standard antibiotic, ciprofloxacin. Researchers report that between 1991 and 1999, the proportion of isolates with lowered susceptibility rose from 0.5 percent to 5 percent, while the proportion of isolates with clinical resistance was 2.2 percent in 1999 versus an average of 0.9 percent for the previous four years. The researchers, from Edinburgh University Medical School, feel their data highlights the need for vigilance at a national level in order to obtain complete data regarding the trends of the antibiotic resistance. If left unchecked, the present rate of resistance may cause isolates to become endemic and quinolones will eventually cease to be effective as a primary treatment of gonorrhea.
001218
AD002241

Copyright © 2000 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.